"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

Cell therapy is considered by some as the next frontier in cancer treatment, engineering patients' own immune systems to ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...

IGI, Inc., a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, ...

Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, explains J&J’s ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...